These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes. Bolognese L Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721 [TBL] [Abstract][Full Text] [Related]
3. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both? Silva MA; Donovan JL; Gandhi PJ; Volturo GA Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468 [TBL] [Abstract][Full Text] [Related]
4. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective. Dyke CM Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236 [TBL] [Abstract][Full Text] [Related]
5. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions. Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316 [TBL] [Abstract][Full Text] [Related]
7. Role of glycoprotein IIb/IIIa-receptor inhibitors in managing ST-segment-elevation myocardial infarction. Racine E Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S27-36. PubMed ID: 12434712 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention. Cheng JW Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S5-14. PubMed ID: 12434710 [TBL] [Abstract][Full Text] [Related]
10. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices. Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601 [TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. Bolognese L; Falsini G; Liistro F; Angioli P; Ducci K; Taddei T; Tarducci R; Cosmi F; Baldassarre S; Burali A J Am Coll Cardiol; 2006 Feb; 47(3):522-8. PubMed ID: 16458130 [TBL] [Abstract][Full Text] [Related]
12. Intracoronary use of GP IIb/IIIa inhibitors in percutaneous coronary interventions. De Vita M; Coluccia V; Burzotta F; Romagnoli E; Trani C Curr Vasc Pharmacol; 2012 Jul; 10(4):448-53. PubMed ID: 22339256 [TBL] [Abstract][Full Text] [Related]
13. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes. Keating FK; Whitaker DA; Sobel BE; Schneider DJ Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562 [TBL] [Abstract][Full Text] [Related]
14. Antiplatelet intervention in acute coronary syndrome. Arora RR; Rai F Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648 [TBL] [Abstract][Full Text] [Related]
15. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study. Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ; Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503 [TBL] [Abstract][Full Text] [Related]
16. Current issues with glycoprotein IIb-IIIa antagonists. Schneider DJ Curr Drug Targets; 2011 Nov; 12(12):1813-20. PubMed ID: 21718238 [TBL] [Abstract][Full Text] [Related]
17. Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience. Banihashemi B; Goodman SG; Yan RT; Welsh RC; Mehta SR; Montalescot G; Kornder JM; Wong GC; Gyenes G; Steg PG; Yan AT; Am Heart J; 2009 Dec; 158(6):917-24. PubMed ID: 19958857 [TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. De Luca G; Navarese EP; Cassetti E; Verdoia M; Suryapranata H Am J Cardiol; 2011 Jan; 107(2):198-203. PubMed ID: 21211597 [TBL] [Abstract][Full Text] [Related]
19. Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis. Lang SH; Manning N; Armstrong N; Misso K; Allen A; Di Nisio M; Kleijnen J Curr Med Res Opin; 2012 Mar; 28(3):351-70. PubMed ID: 22292469 [TBL] [Abstract][Full Text] [Related]
20. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study. Leoncini M; Toso A; Maioli M; Bellandi F; Badia T; Politi A; De Servi S; Dabizzi RP Am Heart J; 2005 Sep; 150(3):401. PubMed ID: 16169315 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]